DK2195015T3 - Sammensætning til behandling af prostatacancer - Google Patents
Sammensætning til behandling af prostatacancer Download PDFInfo
- Publication number
- DK2195015T3 DK2195015T3 DK08802829.5T DK08802829T DK2195015T3 DK 2195015 T3 DK2195015 T3 DK 2195015T3 DK 08802829 T DK08802829 T DK 08802829T DK 2195015 T3 DK2195015 T3 DK 2195015T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- composition
- prostate cancer
- prostate
- cancer
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/008771 WO2009046739A1 (en) | 2007-10-09 | 2007-10-09 | Composition for treating prostate cancer (pca) |
PCT/EP2008/008504 WO2009046975A1 (en) | 2007-10-09 | 2008-10-08 | COMPOSITION FOR TREATING PROSTATE CANCER (PCa) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2195015T3 true DK2195015T3 (da) | 2017-06-19 |
Family
ID=39472544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08802829.5T DK2195015T3 (da) | 2007-10-09 | 2008-10-08 | Sammensætning til behandling af prostatacancer |
Country Status (11)
Country | Link |
---|---|
US (5) | US20100305196A1 (da) |
JP (2) | JP5139530B2 (da) |
CN (2) | CN101820900A (da) |
AU (1) | AU2008309931B2 (da) |
BR (1) | BRPI0818320A2 (da) |
CA (1) | CA2696772C (da) |
DK (1) | DK2195015T3 (da) |
ES (1) | ES2633246T3 (da) |
MX (1) | MX2010003768A (da) |
RU (2) | RU2508125C2 (da) |
WO (2) | WO2009046739A1 (da) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
EP2306993B1 (en) * | 2008-05-26 | 2014-03-12 | Universität Zürich | Protamine/rna nanoparticles for immunostimulation |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
CN104321432B (zh) | 2012-03-27 | 2018-08-10 | 库瑞瓦格股份公司 | 包含5′top utr的人工核酸分子 |
AU2013242404B2 (en) | 2012-03-27 | 2018-08-30 | CureVac SE | Artificial nucleic acid molecules for improved protein or peptide expression |
ES2660459T3 (es) | 2012-03-27 | 2018-03-22 | Curevac Ag | Moléculas de ácido nucleico artificiales |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
DK2844282T3 (da) * | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
CN109045289A (zh) | 2013-02-22 | 2018-12-21 | 库瑞瓦格股份公司 | 疫苗接种和抑制pd-1途径的组合 |
HUE055044T2 (hu) | 2013-03-14 | 2021-10-28 | Translate Bio Inc | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények |
PT2968586T (pt) | 2013-03-14 | 2018-11-13 | Ethris Gmbh | Composições de arnm de cftr e métodos e utilizações relacionados |
EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
ES2808076T3 (es) * | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
RU2016109938A (ru) * | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス(rsv)ワクチン |
CA2915712A1 (en) | 2013-08-21 | 2015-02-26 | Margit SCHNEE | Rabies vaccine |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
EP3035955B1 (en) * | 2013-08-21 | 2019-09-11 | CureVac AG | Composition and vaccine for treating lung cancer |
SG11201510748PA (en) * | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
WO2015024667A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Method for increasing expression of rna-encoded proteins |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
BR112016008806A2 (pt) | 2013-11-01 | 2017-10-03 | Pfizer | Vetores para expressão de antígenos associados à próstata |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
SG11201603144QA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Artificial nucleic acid molecules |
CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
CA2946751A1 (en) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Nucleic acid vaccines |
MX2016016170A (es) | 2014-06-10 | 2017-03-28 | Curevac Ag | Metodos y medios para aumentar la produccion de arn. |
SI3766916T1 (sl) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin |
DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、rna含有組成物 |
SG11201708867UA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Immobilized poly(n)polymerase |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
EP3362461B1 (en) | 2015-10-16 | 2022-03-16 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017067592A1 (en) | 2015-10-21 | 2017-04-27 | Biontech Ag | Cytotoxic immunostimulating particles and uses thereof |
WO2017067593A1 (en) * | 2015-10-21 | 2017-04-27 | Biontech Ag | Methods and means for inducing an immune response |
PL3718565T3 (pl) | 2015-10-22 | 2022-09-19 | Modernatx, Inc. | Szczepionki przeciwko wirusom układu oddechowego |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
CN113636947A (zh) | 2015-10-28 | 2021-11-12 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
CA3020343A1 (en) | 2016-04-08 | 2017-10-12 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
CN109312313A (zh) | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法 |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
CN106632633B (zh) * | 2016-11-24 | 2020-03-20 | 浙江海洋大学 | 一种绿侧花海葵抗肿瘤寡肽及其用途 |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
UY37621A (es) | 2017-02-28 | 2018-09-28 | Sanofi Sa | Arn terapéutico que codifica citoquinas |
JP2020513824A (ja) | 2017-03-24 | 2020-05-21 | キュアバック アーゲー | Crispr関連タンパク質をコードする核酸、及びその使用 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
EP3624824A1 (en) | 2017-05-16 | 2020-03-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
MX2020003995A (es) | 2017-10-19 | 2020-07-22 | Curevac Ag | Nuevas moleculas de acido nucleico artificiales. |
US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
CN108624691A (zh) * | 2018-06-22 | 2018-10-09 | 杭州西合精准医疗科技有限公司 | 一种用于判断前列腺疾病的标志物及其应用 |
WO2020131656A1 (en) * | 2018-12-17 | 2020-06-25 | Immune Design Corp. | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US20220307017A1 (en) * | 2019-08-29 | 2022-09-29 | Universität Zürich | Minimal Messenger RNAs and uses thereof |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
EP4135757A1 (en) * | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CN112516296A (zh) * | 2021-02-07 | 2021-03-19 | 无锡市人民医院 | 一种新抗原RNA及免疫佐剂poly(I:C)复合疫苗及其构建方法 |
EP4326312A1 (en) * | 2021-04-19 | 2024-02-28 | Versameb AG | Method of treating lower urinary tract symptoms |
CN114527222A (zh) * | 2022-02-22 | 2022-05-24 | 广州市番禺区中心医院 | 前列腺癌相关标志物及其应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031211A2 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
US6833438B1 (en) * | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
RU2234942C2 (ru) * | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
WO2000049158A2 (en) * | 1999-02-18 | 2000-08-24 | Compugen Ltd. | Psa and klk-2 splicing variants |
JP2003504080A (ja) * | 1999-07-13 | 2003-02-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
EP1619254B1 (en) | 1999-09-09 | 2010-12-22 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
IL150018A0 (en) | 1999-12-06 | 2002-12-01 | Agensys Inc | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
ES2340532T3 (es) * | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. |
DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
DE10201732A1 (de) * | 2002-01-18 | 2003-07-31 | Curevac Gmbh | Präperation von Immunogenen und Impfstoffen auf der Grundlage von RNA |
DK1511768T3 (da) | 2002-06-11 | 2007-08-20 | Glaxosmithkline Biolog Sa | Immunogene sammensætninger |
DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
WO2004016643A2 (en) | 2002-08-16 | 2004-02-26 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
US7179797B2 (en) | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
US7811564B2 (en) * | 2003-01-28 | 2010-10-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
ES2443996T3 (es) * | 2004-04-22 | 2014-02-21 | Agensys, Inc. | Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1 |
DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
ES2937245T3 (es) * | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
CN101252879A (zh) * | 2005-09-02 | 2008-08-27 | 宝洁公司 | 有效的头皮健康状况预测器 |
BRPI0616211A2 (pt) * | 2005-09-19 | 2011-06-14 | Veridex Llc | mÉtodos para o diagnàstico de cÂncer pancreÁtico |
DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
IL183471A0 (en) * | 2007-05-28 | 2007-09-20 | Yaskawa Europ Technology Ltd | Absolute encoder |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
-
2007
- 2007-10-09 WO PCT/EP2007/008771 patent/WO2009046739A1/en active Application Filing
-
2008
- 2008-10-08 MX MX2010003768A patent/MX2010003768A/es active IP Right Grant
- 2008-10-08 CN CN200880110986A patent/CN101820900A/zh active Pending
- 2008-10-08 JP JP2010528313A patent/JP5139530B2/ja not_active Expired - Fee Related
- 2008-10-08 CA CA2696772A patent/CA2696772C/en not_active Expired - Fee Related
- 2008-10-08 RU RU2010118013/10A patent/RU2508125C2/ru not_active IP Right Cessation
- 2008-10-08 WO PCT/EP2008/008504 patent/WO2009046975A1/en active Application Filing
- 2008-10-08 DK DK08802829.5T patent/DK2195015T3/da active
- 2008-10-08 RU RU2013151122/10A patent/RU2583004C2/ru not_active IP Right Cessation
- 2008-10-08 AU AU2008309931A patent/AU2008309931B2/en not_active Ceased
- 2008-10-08 CN CN201510245819.9A patent/CN104840953A/zh active Pending
- 2008-10-08 BR BRPI0818320A patent/BRPI0818320A2/pt not_active Application Discontinuation
- 2008-10-08 ES ES08802829.5T patent/ES2633246T3/es active Active
- 2008-10-08 US US12/682,187 patent/US20100305196A1/en not_active Abandoned
-
2012
- 2012-11-15 JP JP2012251528A patent/JP5635058B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-05 US US13/759,542 patent/US9402887B2/en active Active
-
2016
- 2016-06-30 US US15/198,456 patent/US10434154B2/en active Active
- 2016-09-20 US US15/271,122 patent/US20170000871A1/en not_active Abandoned
-
2019
- 2019-08-22 US US16/548,112 patent/US20190365879A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2009046975A1 (en) | 2009-04-16 |
RU2508125C2 (ru) | 2014-02-27 |
CA2696772C (en) | 2017-09-05 |
US20190365879A1 (en) | 2019-12-05 |
WO2009046739A1 (en) | 2009-04-16 |
US20100305196A1 (en) | 2010-12-02 |
MX2010003768A (es) | 2010-04-30 |
US20130251742A1 (en) | 2013-09-26 |
JP5139530B2 (ja) | 2013-02-06 |
AU2008309931A1 (en) | 2009-04-16 |
RU2013151122A (ru) | 2015-05-20 |
RU2010118013A (ru) | 2011-11-20 |
US20160303210A1 (en) | 2016-10-20 |
JP5635058B2 (ja) | 2014-12-03 |
RU2583004C2 (ru) | 2016-04-27 |
US10434154B2 (en) | 2019-10-08 |
CA2696772A1 (en) | 2009-04-16 |
US9402887B2 (en) | 2016-08-02 |
BRPI0818320A2 (pt) | 2015-09-08 |
JP2010540673A (ja) | 2010-12-24 |
JP2013082711A (ja) | 2013-05-09 |
US20170000871A1 (en) | 2017-01-05 |
AU2008309931B2 (en) | 2013-01-17 |
CN101820900A (zh) | 2010-09-01 |
ES2633246T3 (es) | 2017-09-20 |
CN104840953A (zh) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2195015T3 (da) | Sammensætning til behandling af prostatacancer | |
DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
DK3289876T3 (da) | Forbindelser til behandling af cancer | |
DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
DK2121139T3 (da) | Formulations for cancer treatment | |
DK2154971T3 (da) | Synergistisk farmaceutisk kombination til behandling af cancer | |
DK3354276T3 (da) | Sammensætninger til behandlingen af gastrointestinal inflammation | |
DK1874821T3 (da) | Kombination af antistoffer med glykokortikoider til behandling af kræft | |
DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
DK2076540T3 (da) | Hidtil ukendte anti-cd38-antistoffer til behandling af cancer | |
DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
DK3567035T3 (da) | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer | |
BRPI0810206A2 (pt) | Método de tratar câncer | |
DK2249859T3 (da) | Behandling af metastatisk prostatacancer med degarelix | |
DK2162149T3 (da) | Vaccine til forebyggelse af brystkræfttilbagefald | |
DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
DK2101805T3 (da) | Integrinligander til anvendelse i behandling af cancer | |
DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
BRPI1010874A8 (pt) | composição para o tratamento de câncer de próstata | |
DK2209784T3 (da) | Forbindelser til behandling af hepatitis C | |
DK3246042T3 (da) | Lægemiddelresistent immunterapi til behandling af cancer | |
DK2115069T3 (da) | Varmehærdende sammensætning |